A randomized phase II trial of concurrent temozolomide (TMZ) and radiotherapy (RT) followed by dose-dense compared to metronomic TMZ and maintenance cis-retinoic acid for patients with newly diagnosed glioblastoma multiforme (GBM)

被引：0
|
作者：
Clarke, Jennifer [1 ]
Sul, Joohee [1 ]
DeAngelis, Lisa [1 ]
Lassman, Andrew [1 ]
Hormigo, Adilia [1 ]
Nolan, Craig [1 ]
Gavrilovic, Igor [1 ]
Gu, Bin [1 ]
Panageas, Kathy [1 ]
Abrey, Lauren [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
NEURO-ONCOLOGY | 2007年 / 9卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：530 / 530
页数：1
相关论文
共 50 条
  • [21] NUTMEG: A RANDOMISED PHASE II STUDY OF NIVOLUMAB AND TEMOZOLOMIDE (TMZ) VS TMZ ALONE IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM): TRIAL IN PROGRESS
    Khasraw, Mustafa
    McDonald, Kerrie
    Yip, Sonia
    Verhaak, Roel
    Heimberger, Amy
    Hall, Merryn
    Fisher, Lauren
    Barnes, Elizabeth
    Rosenthal, Mark
    Gedye, Craig
    Hovey, Elizabeth
    Ellingson, Benjamin
    Simes, John
    Tognela, Annette
    Koh, Eng-Siew
    Gan, Hui
    Back, Michael
    Lwin, Zarnie
    NEURO-ONCOLOGY, 2018, 20 : 235 - 235
  • [22] SURVIVAL AND TOXICITY UPDATE OF THE PHASE 2 TRIAL OF BEVACIZUMAB (BV) IN COMBINATION WITH TEMOZOLOMIDE (TMZ) AND RADIATION THERAPY (RT) FOLLOWED BY BV, TMZ, AND IRINOTECAN (CPT-11) FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM) PATIENTS
    Desjardins, Annick
    Reardon, David A.
    Peters, Katherine B.
    Herndon, James E., II
    Kirkpatrick, John P.
    Friedman, Henry S.
    Vredenburgh, James J.
    NEURO-ONCOLOGY, 2010, 12 : 77 - 77
  • [23] NCCTG phase I trial of temsirolimus (CCI-779) and temozolomide (TMZ) in combination with radiation therapy (RT) in newly diagnosed glioblastoma multiforme (GBM) patients
    Sarkaria, J. N.
    Galanis, E.
    Wu, W.
    Giannini, C.
    Jaeckle, K. A.
    Doyle, L.
    Uhm, J.
    Brown, P.
    Dietz, A. B.
    Buckner, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [24] Safety and efficacy of the addition of bevacizumab (BV) to temozolomide (TMZ) and radiation therapy (RT) followed by BV, TMZ, and irinotecan (CPT-11) for newly diagnosed glioblastoma multiforme (GBM)
    Vredenburgh, J. J.
    Desjardins, A.
    Reardon, D. A.
    Peters, K.
    Herndon, J. E., II
    Kirkpatrick, J.
    Gururangan, S.
    Bailey, L.
    Friedman, A. H.
    Friedman, H. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [25] A Phase 2 Trial of Neoadjuvant Temozolomide (TMZ) Followed By Accelerated Hypofractionated Radiation Therapy (AHRT) and TMZ Followed By Adjuvant TMZ in Patients with Newly Diagnosed Glioblastoma (GBM): Long Term Survival and Toxicity Analysis
    Shenouda, G.
    Souhami, L.
    Petrecca, K.
    Owen, S.
    Panet-Raymond, V.
    Carvalho, T.
    Guiot, M. C.
    Abdulkarim, B. S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : S48 - S49
  • [26] Concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM). Conclusive results of a randomized phase III trial by the EORTC Brain & RT Groups and NCIC Clinical Trials Group
    Stupp, R
    Mason, WP
    Van Den Bent, MJ
    Weller, M
    Fisher, B
    Taphoorn, M
    Brandes, AA
    Cairncross, G
    Lacombe, D
    Mirimanoff, RO
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 1S - 1S
  • [27] PHASE III TRIAL OF TUMOR TREATING FIELDS (TTFIELDS) TOGETHER WITH TEMOZOLOMIDE (TMZ) COMPARED TO TEMOZOLOMIDE ALONE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
    Farber, Ori
    Weinberg, Uri
    Palti, Yoram
    NEURO-ONCOLOGY, 2013, 15 : 76 - 77
  • [28] Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM).
    Omuro, A. M. P.
    Beal, K.
    Karimi, S.
    Correa, D.
    Chan, T. A.
    DeAngelis, L. M.
    Gavrilovic, I. T.
    Nolan, C.
    Hormigo, A.
    Lassman, A. B.
    Kaley, T. J.
    Mellinghoff, I. K.
    Grommes, C.
    Panageas, K.
    Reiner, A. S.
    Barradas, R.
    Abrey, L. E.
    Gutin, P. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [29] Phase II Study of Bevacizumab (BEV), Temozolomide (TMZ) and Hypofractionated Stereotactic Radiotherapy (HFSRT) for Newly Diagnosed Glioblastoma (GBM)
    Beal, K.
    Omuro, A.
    Karimi, S.
    Correa, D.
    Chan, T. A.
    DeAngelis, L. M.
    Yamada, Y.
    Abrey, L. E.
    Gutin, P. H.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S129 - S129
  • [30] Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM).
    Omuro, A. A.
    Beal, K.
    Karimi, S.
    Chan, T. A.
    Panageas, K.
    Nayak, L.
    Seko, B.
    DeAngelis, L. M.
    Abrey, L. E.
    Gutin, P. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345